London, Ontario, December 9, 2009 / b3c newswire / - Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the already impressive data package for COTI-2, demonstrating efficacy as a single agent and in combination with first line therapies with low toxicity in seven different animal models of human cancers.
This most recent study was designed to determine first, the effectiveness of oral COTI-2 as a single agent, second, the effectiveness of COTI-2 in combination with gemcitabine, a standard first line therapy for advanced pancreatic cancer, and third, the toxicity of chronically administered oral COTI-2 as a single agent and in combination with gemcitabine in an animal xenograft model of human pancreatic cancer (PANC-1). The following results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional single agent therapy for the treatment of pancreatic cancer:
COTI-2 as a single agent demonstrated efficacy comparable to gemcitabine.
COTI-2 plus gemcitabine was significantly more effective than gemcitabine as a single agent. This result was observed early and increased throughout the duration of the study.
Partial tumor regressions were observed in the combination treatment group.
Chronic oral treatment with COTI-2 as a single agent or in combination with gemcitabine was well tolerated with no treatment deaths or observable toxicity over the duration of the study.
Pancreatic cancer remains the most lethal cancer and effective new treatments are urgently needed. The results of these experiments indicate that chronically administered oral COTI-2 is a well tolerated single agent with efficacy comparable to the first-line agent gemcitabine, and there is